Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Commonwealth of Pennsylvania\u2019s COVID-19 Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melior Pharmaceuticals Awarded Grant for Advancing Pulmonary Therapeutic in COVID-19 Phase 2 Clinical Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melior Pharmaceuticals Receives IND Clearance from US FDA for COVID-19 Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Adhera Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melior Pharmaceuticals Announces Entry Into \u201cLetter-of-Intent\u201d for the Acquisition of Armesocarb by Adhera Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Adhera Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melior Pharmaceuticals Announces Execution of License Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Adhera Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adhera Inks Exclusive License Agreement with Melior Pharmaceuticals for MLR-1023","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Melior Pharmaceuticals

    Menu

    Melior Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Melior Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Adhera Inks Exclusive License Agreement with Melior Pharmaceuticals for MLR-1023

              Details:

              Adhera will license MLR-1023 (tolimidone) from Melior Pharma 1 for the purpose of developing a novel therapeutic for Type 1 diabetes. MLR-1023, a lyn kinase activator, which has shown exceptional clinical safety and tolerability in Phase 2a and Phase 2b Type 2 diabetes.

              Lead Product(s): Tolimidone

              Therapeutic Area: Endocrinology Product Name: MLR-102

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: Adhera Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement August 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Melior Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Melior Pharmaceuticals Announces Execution of License Agreement

              Details:

              Melior has uncovered a previously unreported therapeutic potential of MLR-1019 in PD. As such it represents a new class of PD therapeutic which may be the only drug candidate to address both movement and non-movement aspects of PD.

              Lead Product(s): Armesocarb

              Therapeutic Area: Neurology Product Name: MLR-1019

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Adhera Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Melior Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Melior Pharmaceuticals Announces Entry Into “Letter-of-Intent” for the Acquisition of Armesocarb by Adhera Therapeutics

              Details:

              Under the terms of the intended acquisition, Adhera will continue clinical development of MLR-1019 (Armesocarb ). Melior Pharmaceuticals will receive Adhera stock plus royalties.

              Lead Product(s): Armesocarb

              Therapeutic Area: Neurology Product Name: MLR-1019

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Adhera Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition June 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Melior Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Melior Pharmaceuticals Receives IND Clearance from US FDA for COVID-19 Therapeutic

              Details:

              The planned Phase 2 study is intended to recruit 236 subjects who were recently diagnosed with COVID-19, have early symptoms, but are not hospitalized. Tolimidone will be taken as an orally administered pill once a day.

              Lead Product(s): Tolimidone

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Melior Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Melior Pharmaceuticals Awarded Grant for Advancing Pulmonary Therapeutic in COVID-19 Phase 2 Clinical Trial

              Details:

              The Phase 2 clinical trial is intended to test tolimidone in subjects who were recently diagnosed with COVID19, but are not hospitalized. Tolimidone is expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications.

              Lead Product(s): Tolimidone

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Commonwealth of Pennsylvania’s COVID-19 Vaccines

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Funding September 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY